## A Simple Enantioselective Synthesis of Serratenediol

Junhu Zhang and E. J. Corey\*

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138

corey@chemistry.harvard.edu

Received August 7, 2001

## ORGANIC LETTERS 2001 Vol. 3, No. 20 3215-3216

ABSTRACT



A short synthesis of serratenediol is described, which involves a number of powerful key steps including (1) catalytic enantioselective syntheses of the phenyl sulfone and acylsilane shown above, (2) their coupling, and (3) further stereoselective cationic cyclizations.

Serratenediol (1),<sup>1</sup> a pentacyclic triterpenoid containing a unique seven-membered central ring, is the parent member of a skeletal class of more than 30 natural products.<sup>2</sup> Although the biosynthesis of 1 probably involves the (*S*,*S*)-2,3,22,23-bisepoxide of squalene, it is not clear whether the final cyclization involves tricyclization of the bicyclic epoxide 2 or monocyclization of onocerin (3).<sup>3</sup> In this paper we describe the first enantioselective synthesis of 1 by a short, biomimetic pathway involving a tricyclization of the *N*-phenylcarbamate **13** (Scheme 1).<sup>4</sup>



The control of absolute stereochemistry in the synthesis was achieved using a transition structure designed catalyst

(4) for enantio- and position-selective terminal dihydroxylation of polyprenoids that has recently been described.<sup>5</sup> Thus, reaction of (*E*,*E*)-farnesyl acetate with 1 mol % of 4, 0.5 mol % of K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, 3 equiv of K<sub>3</sub>Fe(CN)<sub>6</sub>, 3 equiv of K<sub>2</sub>CO<sub>3</sub>, and 1 equiv of CH<sub>3</sub>SO<sub>2</sub>NH<sub>2</sub> in 1:1 *t*-BuOH/H<sub>2</sub>O at 0 °C for 4 h produced the triol monoacetate **5**<sup>5.6</sup> of 97% ee in 72% yield (84% based on recovered farnesyl acetate). Transformation of **5** to the bromo acetonide **6** was effected by acetonide formation, deacetylation, and allylic bromide formation, as shown in Scheme 1. Displacement of bromide in **6** by CuCH<sub>2</sub>COOEt<sup>7</sup> afforded the bishomologated ester **7**, which was sequentially transformed into the corresponding alcohol, primary iodide, and phenyl sulfone **8**, as outlined. Reaction of the α-lithio derivative of **8** with the acylsilane **9**<sup>8</sup> provided stereoselectively the *Z*-coupled silyl enol ether

<sup>(1) (</sup>a) Inubushi, Y.; Sano, T.; Tsuda, Y. *Tetrahedron Lett.* 1964, 1303.
(b) Rowe, J. W. *Tetrahedron Lett.* 1964, 2347. (c) Rowe, J. W.; Bower, C. L. *Tetrahedron Lett.* 1965, 2745.

<sup>(2)</sup> Dev, S.; Gupta, A. S.; Potwardhan, S. A. CRC Handbook of Terpenoids. Triterpenoids; CRC Press: Boca Raton, FL, 1987; Vol. II, pp 565-584.

<sup>(3)</sup> Barton, D. H. R.; Overton, K. H. J. Chem. Soc. 1955, 2639.

<sup>(4)</sup> For an earlier synthesis of racemic **1** (in less than 0.01% yield), see: Prestwich, G. D.; Labovitz, J. N. J. Am. Chem. Soc. **1974**, *96*, 7103.

<sup>(5)</sup> Corey, E. J.; Zhang, J. Org. Lett. **2001**, *3*, 3211–3214.

<sup>(6)</sup> Corey, E. J.; Noe, M. C.; Lin, S. *Tetrahedron Lett.* **1995**, *36*, 8741.
(7) Coates, R. M.; Ley, D. A.; Cavender, P. L. J. Org. Chem. **1978**, *43*, 4915.

<sup>(8) (</sup>a) Corey, E. J.; Lin, S. J. Am. Chem. Soc. **1996**, 118, 8765. (b) Corey, E. J.; Lin, S.; Luo, G. Tetrahedron Lett. **1997**, 38, 5771.



<sup>a</sup> (a) (MeO)<sub>2</sub> CMe<sub>2</sub>, cat. p-TsOH, 0.5 h, 23 °C. (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, 1 h, 23 °C. (c) CH<sub>3</sub>SO<sub>2</sub>Cl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 1 h, -42 °C, then 0.5 h, 0 °C; then LiBr, THF, 1 h, 0 °C (91% of 6 from 5). (d) 2 equiv of LDA, 2 equiv of EtOAc, 4 equiv of CuI, THF at -110 °C, then -110 to -30 °C and 1 h at -30 °C (92% of 7 from 6). (e) LiAlH<sub>4</sub>, Et<sub>2</sub>O, 1 h at 23 °C, then 0.5 h at 40 °C. (f) Ph<sub>3</sub>P, imidazole, I2, CH2Cl2, 0.5 h, 23 °C. (g) 2 equiv of PhSO2Na, DMF, 24 h, 23 °C (78% of 8 from 7). (h) 8 + BuLi in 1:1 THF/Et<sub>2</sub>O for 0.5 h at -78 °C, then **9** for 0.5 h at 0 °C (89% of **10**). (i) 1.2 equiv of MeAlCl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0.3 h at -94 °C. (j) Bu<sub>4</sub>NF, THF then 10% KOH in CH<sub>3</sub>OH for 3 h at reflux (75% of 11 from 10). (k) PhNCO, py, 12 h at 23 °C. (l) CH<sub>3</sub>PPh<sub>3</sub>Br, KOtBu, C<sub>6</sub>H<sub>6</sub>, 2 h at 80 °C (68% of 12 from 11). (m) 3:1 HOAc/H<sub>2</sub>O, 5 h at 50 °C. (n) CH<sub>3</sub>SO<sub>2</sub>Cl, py, 12 h at 23 °C. (o) K<sub>2</sub>CO<sub>3</sub>/MeOH, 5 h at 23 °C (80% of 13 from 12). (p) 1.3 equiv of MeAlCl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 1 h at -78 °C. (q) 40% KOH, MeOH, 1.5 h at 100 °C, then silica gel chromatography (21% of 1 from 13).

**10**, in a second key step in the synthesis of **1**. Conversion of **10** to the bicyclic hydroxy ketone **11** was effected by MeAlCl<sub>2</sub>-catalyzed, epoxide-initiated cationic cyclization followed by treatment of the product with  $Bu_4NF$  to cleave

silyl ethers formed during this conversion and then methanolic base to convert any C( $\alpha$ ) axial diastereomer to the more stable equatorial form **11**. The hydroxyl group of **11** was protected as the phenylcarbamate, and the acetonide unit was transformed in the usual way to the epoxide subunit of **13**. Finally, MeAlCl<sub>2</sub>-catalyzed tricyclization of **13** followed by deprotection and silica gel chromatography gave levorotatory serratenediol corresponding to the natural product by comparison of <sup>1</sup>H and <sup>13</sup>C NMR spectra, infrared spectrum, optical rotation, and melting point.<sup>1,2,9</sup>



The success of the short and simple synthesis of the complex serratenediol structure **1** by the pathway shown in Scheme 1 depended on several crucial steps, including the application of catalyst **4** to the construction of chiral glycol **5**, the stereoselective coupling of **8** and **9** to form **10**, and the cationic cyclizations used to generate **11** and **14**. The power of these epoxide-initiated, stereoselective cationic cyclizations, nonenzymic mimics of biosynthetic processes, is clearly demonstrated here, as it has been in other recent syntheses.<sup>10</sup>

**Acknowledgment.** This research was supported by a Canadian NSERC fellowship and by Pfizer Inc.

**Supporting Information Available:** Full experimental procedures for the synthesis of **1** from geranyl and farnesyl acetate. This material is available free of charge via the Internet at http://pubs.acs.org.

## OL016543A

<sup>(9)</sup> Fang, J.-M.; Tsai, W.-Y.; Cheng, Y.-S. Phytochemistry 1991, 30, 1333.

<sup>(10)</sup> See, for example: (a) Huang, A. X.; Xiong, Z.; Corey, E. J. J. Am. Chem. Soc. 1999, 121, 9999. (b) Corey, E. J.; Lin, S. J. Am. Chem. Soc. 1996, 118, 8765. (c) Corey, E. J.; Luo, G.; Lin, S. J. Am. Chem. Soc. 1997, 119, 9927. (d) Corey, E. J.; Lee, J. J. Am. Chem. Soc. 1993, 115, 8873. (e) Corey, E. J.; Lie, J.; Liu, D. R. Tetrahedron Lett. 1994, 35, 9149.